Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07078695
PHASE1

A Trial of SHR-1139 in Healthy Volunteers

Sponsor: Atridia Pty Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess safety, PK and immunogenicity profile of a single dose of SHR-1139 in healthy volunteers

Official title: A Phase 1, Randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Subcutaneous/Intravenous Administered SHR-1139 in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2025-08-19

Completion Date

2026-09-30

Last Updated

2026-03-19

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

SHR-1139 Injection

Single dose of SHR-1139 given subcutaneously (dose level 1 )

DRUG

SHR-1139 Injection

Single dose of SHR-1139 given subcutaneously (dose level 2 )

DRUG

SHR-1139 Injection

Single dose of SHR-1139 given intravenously (dose level 3)

Locations (1)

Linear

Perth, Western Australia, Australia